Sou Hu Cai Jing·2026-02-01 18:12Core Viewpoint - Junshi Biosciences (688180) reported a decline in stock price and significant financial losses for 2025, despite an expected increase in revenue driven by improved commercialization capabilities and cost control measures [1]. Trading Information Summary - On January 30, the main funds experienced a net outflow of 20.37 million yuan, accounting for 3.53% of the total transaction amount; retail investors had a net outflow of 6.18 million yuan, representing 1.07% of the total transaction amount; however, speculative funds saw a net inflow of 26.55 million yuan, making up 4.61% of the total transaction amount [1]. Performance Disclosure Highlights - Junshi Biosciences anticipates a total revenue of approximately 2.5 billion yuan for the year 2025, reflecting a year-on-year growth of 28.32%; however, the net profit attributable to the parent company is expected to be a loss of about 873 million yuan, which is a reduction of 31.85% compared to the previous year [1]. Company Announcement Summary - The sales revenue of Toripalimab injection in the domestic market has significantly increased, with all 12 approved indications included in the national medical insurance catalog, which is expected to drive commercial revenue growth [1]. - The company is continuing to advance multiple innovative drug clinical trials, including JS207 and JS212 [1].